| Northern Oral & Maxillofacial Surgeons, Pa | |
|
3617 W Arrowhead Rd Duluth MN 55811-4046 | |
| (218) 722-8377 | |
| (218) 722-3117 |
| Full Name | Northern Oral & Maxillofacial Surgeons, Pa |
|---|---|
| Speciality | Dentist |
| Location | 3617 W Arrowhead Rd, Duluth, Minnesota |
| Authorized Official Name and Position | Charles R Babst (PRESIDENT) |
| Authorized Official Contact | 2187228377 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Northern Oral & Maxillofacial Surgeons, Pa 3617 W Arrowhead Rd Duluth MN 55811-4046 Ph: (218) 722-8377 | Northern Oral & Maxillofacial Surgeons, Pa 3617 W Arrowhead Rd Duluth MN 55811-4046 Ph: (218) 722-8377 |
| NPI Number | 1457401820 |
|---|---|
| Provider Enumeration Date | 01/10/2007 |
| Last Update Date | 03/05/2008 |
| Medicare PECOS PAC ID | 3072535863 |
|---|---|
| Medicare Enrollment ID | O20051221000235 |
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457401820 | NPI | - | NPPES |
| 60360BA | Other | MN | MINNESOTA BCBS CLINIC |
| 38393400 | Other | WI | WISCONSIN MEDICAID CLINIC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | 2467529001 (Minnesota) | Primary |
| Provider Name | Peter J Mayer |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1104976570 PECOS PAC ID: 1951323732 Enrollment ID: I20051221000179 |
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
| Provider Name | Duncan R Puffer |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1073663449 PECOS PAC ID: 6002824463 Enrollment ID: I20100316001045 |
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
| Provider Name | Marty J Espe |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1760532139 PECOS PAC ID: 7911915376 Enrollment ID: I20110110000877 |
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
| Provider Name | Timothy Lee Morse |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1225264575 PECOS PAC ID: 0547409179 Enrollment ID: I20130612000025 |
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
| Provider Name | Benjamin T Heggestad |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1598146763 PECOS PAC ID: 5294047569 Enrollment ID: I20150701000801 |
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
News Archive
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company's IP portfolio.
A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.
The American College of Physicians (ACP) today urged the Department of Health and Human Services (HHS) to use the International Classification of Diseases (ICD-10) implementation delay to consider specifying the use of Systemized Nomenclature of Medicine - Clinical Term (SNOMED-CT), rather than ICD-10, for coding problems in all situations.
› Verified 2 days ago
Dental Specialist Of Minnesota, Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 324 W Superior St Ste 824, Duluth, MN 55802 Phone: 218-727-1182 | |
Richard W Oase Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 306 W Superior St, Suite 601, Duluth, MN 55802 Phone: 218-727-2349 Fax: 218-727-2531 | |
Oral And Maxillofacial Surgical Associates Dental Clinic Medicare: Medicare Enrolled Practice Location: 1000 East First Street #302, Duluth, MN 55805 Phone: 218-722-1854 Fax: 218-722-6424 | |
Mount Royal Dental Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1624 Woodland Ave, Duluth, MN 55803 Phone: 218-464-5222 Fax: 218-464-5229 | |
Pdg, Pa Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 906 Woodland Ave, Duluth, MN 55812 Phone: 218-606-1040 Fax: 218-606-1060 | |
Chester Creek Dental Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1324 E 1st St, Duluth, MN 55805 Phone: 218-724-1332 Fax: 218-724-2184 | |
Daniel J Loban Dds Pa Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1011 E Central Entrance, Duluth, MN 55811 Phone: 218-722-1715 Fax: 218-727-3217 |